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Balanitesaegyptiaca(Balanitaceae)isawidelygrowndesertplantwithmultiusepotential.Inthepresentpaper,acrudeextractfrom
B. aegyptiaca seeds equivalent to a ratio of 1:2000 seeds to the extract was screened for antiplasmodial activity. The determined
IC50 value for the chloroquine-susceptible Plasmodium falciparum NF54 strain was 68.26µg/µL±3.5. Analysis of the extract by gas
chromatography-massspectrometrydetected6-phenyl-2(H)-1,2,4-triazin-5-oneoxime,aninhibitoroftheparasiticM18Aspartyl
Aminopeptidase as one of the compounds which is responsible for the in vitro antiplasmodial activity. The crude plant extract had
a Ki of 2.35µg/µL and showed a dose-dependent response. After depletion of the compound, a signiﬁcantly lower inhibition was
determined with a Ki of 4.8µg/µL. Moreover, two phenolic compounds, that is, 2,6-di-tert-butyl-phenol and 2,4-di-tert-butyl-
phenol, with determined IC50 values of 50.29µM ± 3 and 47.82µM ± 2.5, respectively, were detected. These compounds may
contribute to the in vitro antimalarial activity due to their antioxidative properties. In an in vivo experiment, treatment of BALB/c
mice with the aqueous Balanite extract did not lead to eradication of the parasites, although a reduced parasitemia at day 12 p.i.
was observed.
1.Introduction
Traditional medicine is still the ﬁrst point of healthcare for
many people in sub-Saharan Africa, where there has been a
long and rich tradition of obtaining treatments from herbs
and trees. In the case of malaria, Africa’s traditional healers
use hundreds of indigenous plants for remedies.
Until the 1950s, when synthetic chemistry began to
dominate drug research and development (R and D) eﬀorts,
most drugs developed and registered in the pharmacopoeia
were in fact based on natural products. Plant alkaloids,
quinine among them, were the ﬁrst components of natural
herbalremediestobeextractedandreﬁnedformoreeﬀective
use in the early 19th century. Some 150 years later, quinine is
still used as front-line therapy for severe malaria, even if it
is not the recommended drug for this use when artemisinin
combinationtherapies(ACTs)areavailable.Inthiscontext,it
seemstobequitesurprisingthatnoAfricanleadhasemerged2 Journal of Parasitology Research
so far. Meanwhile, there are eﬀorts to assess plant remedies
against malaria for their application in health care systems
[1].
B. aegyptiaca (L.) (Balanitaceae) is a woody tree growing
in various ecological conditions (from 100mm to 1000mm
annual rainfall), but mainly distributed in semiarid and arid
zones in tropical Africa [2]. This tree reaches 10m (33ft) in
height with a generally narrow form and thorny branches.
The tree produces several forms of inﬂorescence bearing
yellow-green bisexual ﬂowers which exude nectar. In Egypt,
it is conﬁned to water-receiving sites, that is, wadis and river
banks.
B. aegyptiaca has been applied for a variety of indications
in traditional medicine. Its fruit has been the basis for an
active trade in many centuries because of its oil, which
consistsoflinearandbranchedchainalkaneswhilethekernel
contains terpenes and sterols (diosgenin), which showed a
reduction of liver cholesterol [3].
The bark was formerly used as a ﬁsh poison, presumably
because of its steroidal saponin content as the active compo-
nent [4]. Aqueous extracts of the bark showed antibacterial,
antifungal and antiviral activity [5], but most notable was
theantifungaleﬀectofB.aegyptiacaagainstCandidaalbicans
infections [5].
Balanitin-6 and balanitin-7 are diosgenyl saponins from
B. aegyptiaca kernels and they demonstrated appreciable
anticancer eﬀects in human cancer cell lines in vitro [6]
with a higher antiproliferative potential than etoposide and
oxiplatin. The anticancer activity mainly results from a
depletion of ATP leading in turn to a major disorganization
o fa c t i nc y t o s k e l e t o n[ 6].
The structures of balanitins, that is, balanitin-1, -2, -3,
are composed of steroid glycosides proven to be potent
molluscicides for the control of freshwater snails that are car-
riers of bilharzia [7]. Moreover, the eﬃcacy of B. aegyptiaca
fruit mesocarp was compared with praziquantel in infected
mice with a Sudanese strain of Schistosoma mansoni [8]. A
single dose of 200mg/kg body weight reduced the recovery
of adult worms signiﬁcantly. Recently, root-derived callus
from B. aegyptiaca with 500ppm extracted saponins showed
a larvicidal eﬀect of 100% against Aedes aegypti mosquito
larvae [9].
Over recent years, resistance of malaria parasites to ther-
apy has increased the need to develop alternative treatments.
Since B. aegyptiaca bark shows promising anti-infective
properties, we investigated its potential antiplasmodial activ-
ityinseedsandrelatedthisactivitytoitsconstituentsinvitro.
Although phytochemical analyses and medicinal evaluations
have been recently performed for ﬁxed oil from B. aegyptiaca
fruits [10], in vivo biological assays are missing. Here,
we monitored parasitemia after application of an aqueous
extract obtained from the seeds of the plant in vitro and in
vivo in BALB/c mice.
2.MaterialandMethods
2.1. Plant Material. Seeds of B. aegyptiaca (Balanitaceae)
were obtained from Harraz pharmacy in Cairo, collected in
the area of Ras Mohammed National Park and botanically
identiﬁed by Professor G¨ ortz, Biological Institute, University
of Stuttgart, Germany.
2.2. Soxhlet Extraction. B. aegyptiaca seeds (5g) were pow-
dered and incubated at 37◦C in 100mL distilled water.
To facilitate dissolution of the steroid aglyca, squalane
solution (1mL) (Sigma-Aldrich, Munich, Germany) made
with 2NHCl was added, and the mixture was reﬂuxed
with 200mL methanol for 24 hours in a Soxhlet apparatus.
The extract was dried with calcium sulfate (CaSO4·2H2O)
(Carl Roth, Karlsruhe, Germany) and ﬁltered. Subsequently,
methanol was evaporated by using the rotary evaporator
and a vacuum pump. The residue obtained was diluted
in 50mL methanol by sonication and analyzed by gas
chromatography-mass spectrometry (GC/MS).
For the preparation of an aqueous extract, 5g of pow-
dered B. aegyptiaca seeds were incubated at 37◦C in 100mL
distilled, autoclaved water for 24 hours in a sealed, sterilized
Falcon tube and ﬁltrated in a laminar air ﬂow under aseptic
conditions.
2.3. GC/MS Instrumentation and Analytical Conditions.
GC/MS measurements were made using a 7890A gas chro-
matograph with a series 7683B autosampler and a series
5975C quadrupole mass spectrometer (Agilent Technologies
Inc., Santa Clara, CA, USA) operated in electron impact
ionization(EI)mode.Thefusedsilicacapillarycolumn,30m
l o n g ,0 . 2 5 m mI .D .w i t hHP-5MS stationary phase, ﬁlm
thickness 0.25µm was used. GC/MS data were processed
with the ChemStation software (Agilent Technologies) and
the NIST 05 mass spectra library (Agilent Technologies).
The temperature of the column was programmed from 80◦C
(1min hold) at 10◦Cmin −1 to 280◦C (50min hold). Helium
5.0 grade (Westfalen AG, M¨ unster, Germany) was used as
a carrier gas. Constant ﬂow of helium of 1.0cm3 min−1
was used during the entire analysis. The temperature of
the split/splitless injector was 250◦C, and the split ﬂow was
10cm3 min−1. The transfer line temperature was 280◦C. The
EI ion source temperature was kept at 230◦C. The ionization
occurred with a kinetic energy of the impacting electrons
of 70eV (electron volts). The quadrupole temperature was
150◦C. Mass spectra and reconstructed chromatograms
(total ion current [TIC]) were obtained after eluting of
solvent (7min solvent delay) by automatic scanning in the
mass range m/z 30–750u.
2.4. Cultures of P. falciparum Isolate NF54. P. falciparum
isolate NF54, which was obtained from Malaria Research
and Reference Center, Manassas, VA, USA, was maintained
in continuous culture with gentamicin (40µg/mL) in petri
dishes (5cm in diameter) with a gaseous phase of 90%
N2,5 %O 2, and 5% CO2, according to a protocol from
Molony et al. 1990 [11] and Trager and Williams 1992
[12]. Parasites were cultured in human erythrocytes (blood
group A+) in RPMI 1640 medium (Sigma) supplemented
with 25mM HEPES, 20 mM sodium bicarbonate, and 10%
heat-inactivated human A+ plasma at 10% (v/v) hematocrit.Journal of Parasitology Research 3
The parasitemia of the infected erythrocytes was determined
in Giemsa-stained smears by light microscopy. Parasitemias
and morphological forms detected in the cultures were
scored visually with a 100-fold oil-immersion objective,
counting at least 1,000 erythrocytes to determine the per-
centage of the infected erythrocytes [13]. A drug-free control
(methanol/water 50:50% v,v) was used in all experiments.
2.5.MonitoringMultiplicationandGrowthofPlasmodia. The
culture was adjusted to a parasitemia of 1.5%. Aliquots
(200µL) were suspended in 2mL RPMI-medium (Sigma-
Aldrich) supplemented with 25mM HEPES, 20mM sodium
bicarbonate, and 10% heat-inactivated human A+ plasma at
10% (v/v) hematocrit, dispensed into 12-well microculture
trays, and incubated at 37◦C in a gaseous atmosphere of
90% N2,5 %O 2, and 5% CO2. Thereafter, growth medium
was changed once a day for 4 days, and 2,4-di-tert-butyl-
phenol and 2,6-di-tert-butyl-phenol stock solutions were
dissolved in water/methanol mixture (50/50%, v/v) before
beingdilutedinRPMIgrowthmediumintheconcentrations
given for each experiment.
Dilution of the crude Balanite extract obtained after
Soxhlet extraction was performed with RPMI-growth
medium as a solvent to protect the RBC membrane from
perturbation.
Parasitemia and stage distribution were estimated as
triplicates daily from Giemsa-stained smears by counting
1,000 erythrocytes.
2.6. Determination of the IC50 Values. The 50% inhibitory
concentrations (IC50s), deﬁned as the drug concentration
corresponding to 50% inhibition of parasitic growth were
determined by nonlinear regression analysis.
Data obtained from the inhibitor-dependent concentra-
tion growth curves were computed into plots with nonlinear
regression analysis from y-axis (inhibition %) to x-axis
(inhibitor concentration µM) [14].
2.7. Animals. The animal studies were performed according
to the guidelines of the German Animal Welfare Act (license
number: 50.203. 2-BN). Balb/c2 mice were maintained and
bred at the animal facility of the University of Bonn and
infected intravenously with 1×105 parasitized erythrocytes
from a homologous donor mouse, which had been infected
with frozen polyclonal stocks of P. berghei ANKA (PbA)
strain. BALB/c mice developed a Th2 response and did
not succumb to cerebral malaria, but died after 10–30 days
becauseof high parasitemia and anemia. 50µlof the aqueous
crude plant extract (1,25g/100mL) were applied to the
BALB/c mice intraperitoneally (i.p.) on days 3, 2, 1 before
infection, at the day of infection, and on days 1, 2, 3, 4, 5, 6,
after infection. Control mice were treated with 200µL PBS-
buﬀer, and the same scheme of administration was applied.
2,6-di-tert-butyl-phenol and 2,4-di-tert-butyl-phenol
were applied to the BALB/c2 mice intraperitoneally (i. p.)
on days 4 and 2 before infection, and on days 2, 4, and
6 before infection. Chloroquine was applied i. p. on days
1–8 post infection in a concentration of 25mg/kg for each
mouse. Giemsa-stained smears were performed on days
1,2,3,4,5,7,6,8,10, and 12, and 15. 5mice were treated in
each group.
2.8. Recloning of P. falciparum M18 Aspartyl Aminopepti-
dase (PFM 18 AAP). The nucleic acid sequence from P.
falciparum M18 Aspartyl Aminopeptidase was chemically
synthesized by GenScript (NJ, USA) with optimization of
codon usage as described by Teuscher et al. (2007) [15]. A
subclonewassubsequentlyconstructedwithBaculoDirectC-
terminal linear DNA (Invitrogen, Germany) and transfected
into Sf9 (Spodoptera frugiperda) cells for protein expression
and puriﬁcation according to Teuscher et al. (2007) [15].
2.9. Activity Assay of the P. falciparum M18 Aspartyl
Aminopeptidase (PFM 18 AAP). The activity assay was per-
formed according to a high-throughput-screening (HTPS)
described by Teuscher et al. 2007 [15] and by the
Scripps Research Institute Molecular Screening Center
(http://mlpcn.ﬂorida.scripps.edu/).
Prior to the start of the assay, 2.5µLo fa s s a yb u ﬀer
(50mM Tris HCl pH 7.5, 4mM CoCl2, 0.1% BSA) contain-
ing 5 µg/mL recombinant PFM 18 AAP were dispensed into
a 12-well microtiter plate. Next, 37µL of the crude Balanite
extract and the “depleted Balanite extract” where 6-phenyl-
2(H)-1,2,4-triazin-5-one oxime was absent were added as
a control reaction to the appropriate wells. Depletion of
the extract was performed by liquid chromatography-mass
spectrometry (LC/MS), and fractions were rechecked by
GC/MS as described within for the presence and absence of
the 6-Phenyl-2(H)-1,2,4-triazin-5-one oxime.
The plates were incubated for 30 minutes at 25◦C. The
assay was started by dispensing 2.5µL of 100µM H-Glu-
NHMec as a ﬂuorogenic peptide (GenScript, NJ, USA) in
buﬀer (50mM Tris HCl, pH 8.8) into all wells. Fluorescence
was read immediately (T0) on the ViewLux (Perkin-Elmer,
MA, USA) and again after 90 minutes (T90) of incubation at
25◦C. Prior to further calculations, T0 was substracted from
T90.T h r e ed i ﬀerent experiments for each concentration were
performed.
2.10. Statistics. Statistical analyses were performed using
GraphPad Prism software to evaluate the in vivo inhibitor
experiments performed with BALB/c mice. Normality of
data distribution was assessed by the Kolmogorov-Smirnov
normalitytest.Nonparametricallydistributeddatawereana-
lyzed using the Mann-Whitney test for diﬀerences between
the aqueous Balanite extract and the chloroquine treated
group.
3. Results
Crude extracts from extracted Balanites aegyptiaca seeds
show antiplasmodial activity in the chloroquine susceptible P.
falciparum strain NF54 in vitro.
In vitro inhibition of growth of the chloroquine sus-
ceptible P. falciparum strain NF54 was tested with a crude
extract from B. aegyptiaca (the amount equivalent to 1:20004 Journal of Parasitology Research
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Figure 1: (a) Growth of the chloroquine-susceptible P. falciparum
strain NF54 in the presence of a diluted extract from Balanite seeds
obtained from a 1:2000 ratio of seeds to extract. Parasites were
grownin12-wellmicroculturetrays.Trianglesindicateparasitemias
of the untreated NF54 control while rectangles indicate the drug-
treated strain. Each point represents the mean value of four
diﬀerent determinations with±standard deviations. (b) Dose-
response curve of the crude extract from Balanite seeds (extract
mg/mL) versus the percentage of the determined parasitemia.
of a seed) obtained by Soxhlet extraction which led to an
eradication of the parasite within 3 days (Figure 1(a))a n d
a determined IC50 of 68.26µg/µL±3,5 (Figure 1(b)). By
contrast, the untreated NF54 strain showed normal growth.
The crude Balanite extract and a dilution of the extract, in
which the ratio of seeds to the extract was 1:200, lysed red
blood cells (RBC; data not shown). Therefore, the amount
equivalent to 1:2000 of a seed was applied with RPMI-
medium as a solvent to avoid any perturbation of the
erythrocyte membrane.
Figure 2 shows the chromatogram of the total ion
current (TIC) obtained by GC/MS analysis of the crude
Balanite extract to identify and characterize the active
compounds of the crude extract after Soxhlet extraction.
Figures 3(a)–3(c) represent the mass spectra of the identiﬁed
peaks using pure standard substances and the peaks of the
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Figure 2: Chromatogram of the total ion current (TIC) obtained
by GC/MS analysis of the crude Balanite extract. The x-axis of
each GC/MS chromatogram represents the minutes of retention.
The chromatogram shows the detected substances with retention
times of 2,6-di-tert-butyl-phenol (18.43min), 2,4-di-tert-butyl-
phenol (19.36min), and 6-phenyl-2(H)-1,2,4-triazin-5-one oxime
(39.44min).
NIST 05 mass spectra library of compounds for comparison
and to elucidate the chemical structures of the detected
substances 2,6-di-tert-butyl-phenol (18.43min), 2,4-di-tert-
butyl-phenol (19.36min), and 6-phenyl-2(H)-1,2,4-triazin-
5-one oxime (39.44min), respectively. Ion [M]+. at m/z 206,
the fragment ion [M –CH3]+ at m/z 191 and the [C4H9]+
ion at m/z 57 are characteristic for both di-tert-butyl-phenol
isomers (Figures 3(a)–3(b)).
The crude Balanite extract inhibited recombinant M18
Aspartyl Aminopeptidase from Plasmodium falciparum
(PFM18AAP) with a determined Ki of 2.34µM. The assay
was performed with a commercially available ﬂuorogenic
peptide substrate H-Glu-NHMec. Cleavage of the substrate
by recombinant PFMAAP enzyme liberates the NHMec
fromthepeptide,leadingtoincreasedﬂuorescence.Diﬀerent
concentrations of the crude plant extract (Figure 4,b l u e
curve) were applied to investigate the dose response of
recombinantPFMAAP.InhibitionofPFM18AAPwasstrictly
dose dependent. In parallel, we determined the inhibitory
eﬀect of recombinant PFM18AAP after fractionation of the
Soxhlet extract pooling fractions in which 6-phenyl-2(H)-
1,2,4-triazin-5-one oxime was absent (Figure 4, pink curve).
The absence of the compound was conﬁrmed by GC/MS
analysis. The pink curve in Figure 4 shows that depletion
of6-phenyl-2(H)-1,2,4-triazin-5-oneoximefromtheextract
leads to a 50% lower inhibition at concentrations ranging
from 2.7ng dry weight per ml to 73.5ng dry weight per mL
compared to the extract where the compound was present.
The determined Ki was 4.8µg/µl.
Derivatives of 6-phenyl-2(H)-1,2,4-triazin-5-one have
been recently identiﬁed as important inhibitor lead struc-
tures for recombinant plasmodial M18 aminopeptidase
(PfM18AAP) in a biochemical high-throughput screening
assay (HTPS) with ﬂuorogenic peptide substrate (The
Scripps Research Institute Molecular Screening Center,
http://mlpcn.ﬂorida.scripps.edu/). The derivatives of 6-
phenyl-2(H)-1,2,4-triazin-5-one that is, 3-(benzylamino)-4-
ethyl-6-phenyl-1,2,4-triazin-5-one oxime were applied in a
concentration of 7.35µM and inhibited the recombinantJournal of Parasitology Research 5
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Figure 3: Mass spectra and structural formula of the identiﬁed
compounds, using pure standard substances and the NIST 05 mass
spectra library. The x- a x i so fe a c hm a s ss p e c t r u ms h o w st h em/z
(mass to charge) units. (a) 2,6-di-tert-butyl-phenol, (b) 2,4-di-tert-
butyl-phenol, and (c) 6-phenyl-2(H)-1,2,4-triazin-5-one oxime.
enzyme to 31%. This inhibitory eﬀect has been attributed to
formation of metal chelates with the cocatalytic zinc metal
ions of the parasitic enzyme. Taken together, these results
suggest that the detected 6-phenyl-2(H)-1,2,4-triazin-5-one
oxime might contribute to the antiplasmodial activity.
The occurrence of the two phenolic compounds prompt-
ed us to perform in vitro inhibitor and dose-response
experiments with P. falciparum strain NF54 at concentra-
tions from 10mM to 100mM. For this experiment the
commercially available pure phenolic compounds (Fluka,
Germany) were applied. Inhibition of growth started at
0
10
20
30
40
50
60
70
80
90
100
0 1 02 03 04 05 06 07 08 0
×103
Crude extract concentration (ng dry weight/µL)
I
n
h
i
b
i
t
i
o
n
(
%
)
Figure 4: Dose-response curve of crude Balanite extract on P.
falciparumM18AspartylAminopeptidase(PFM18AAP).Diﬀerent
concentrations of the crude Balanite extract (µg/mL) were applied
in the in vitro activity assay of PFM 18AAP enzyme as described
within the experimental section. The percentage of inhibition (y-
axis) was plotted versus the extract concentration (x-axis). The blue
curve represents the crude Balanite extract with 6-phenyl-2(H)-
1,2,4-triazin-5-one oxime while the pink curve shows the depleted
extract where the compound is absent.
a concentration of 10mM independently of the compound.
The most prominent growth arrest was observed at a con-
centration of 100mM with either 2,4-di-tert-butyl-phenol
or 2,6-di-tert-butyl-phenol (Figures 5(a) and 5(c),r e s p . ) .
The determined IC50 values were 50.29µM±3 for 2,6-di-
tert-butyl-phenol (Figure 5(b)) and 47.82µM±2,5 for 2,4-
di-tert-butyl-phenol (Figure 5(d)), respectively.
A complete eradication of the parasite was not observed,
suggesting that these compounds may contribute to the
biological activity of the crude plant extract. 2,4-di-tert-
butyl-phenol was more potent than the 2,6-substituted
compound but did not lead to complete eradication of the
parasite. In the next set of experiments, both compounds
(100mM each) were applied for combined treatment. The
combination of both compounds showed an IC50 value
of 42.5µM± 3( Figure 5(f)). Taken together, these results
suggest that the combination of both drugs appear to have
an additive eﬀect.
An aqueous extract from B. aegyptiaca seeds and the two
phenoliccompounds2,4-di-tert-butyl-phenoland2,6-di-tert-
butyl-phenol tested in vivo in BALB/c mice do not reduce
parasitemia.
Hitherto, no in vivo biological activity assay has been
performed to investigate antiplasmodial activity of the
Balanite extract. Therefore, we monitored in vivo protection
in BALB/c infected mice after infection with 105 para-
sitized erythrocytes of P. berghei ANKA (PbA) strain after
administration of the Balanite extract and the two phenolic
compounds, that is, 2,4-di-tert-butyl-phenol and 2,6-di-
tert-butyl-phenol. The crude aqueous plant extract (50mL
of 1,25g dry extract/100mL solvent) was intraperitoneally
applied on days 3, 2, and 1 before infection, at the day of
infection, and on days 1,2,3,4,5,6,7, and 8 after infection.
The two phenolic compounds (each dose was 6mg/kg body
weight) were intraperitoneally applied on days 4 and 2
before infection and on days 2, 4, and 6 after infection. At6 Journal of Parasitology Research
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Figure 5: In vitro inhibition and dose-response curves of chloroquine-susceptible P. falciparum strain NF54. Parasitemias determined after
inhibition with (a) 100µM 2,6-di-tert-butyl-phenol, (c) 100µM 2,4-di-tert-butyl-phenol, and (e) a combination of both compounds with
100µM each. Triangles indicate parasitemias of the untreated NF54 control while rectangles indicate the drug-treated strain. Each point
represents the mean value of four diﬀerent countings with±standard deviations. Dose-response curves were obtained after inhibition
with the compounds in the range of 10µM–100µMa n dI C 50 values were determined. (b) 2,6-di-tert-butyl-phenol, determined IC50 =
50.29µM±3, and (d) 2,4-di-tert-butyl-phenol, determined IC50 = 47.82µM±2,5, and (f) a combination of both compounds determined
IC50 = 42.5µM±3.
day 8p.i., parasitemia was signiﬁcantly increased in mice
treated with the extract whereas, at day 12p.i., a reduction
c o u l db eo b s e r v e dc o m p a r e dt oc o n t r o l s( Figure 6). Loss of
body weight is an indicator of malaria infection. In both
untreated and extract-treated animals, a reduction of weight
could be observed whereas chloroquine treatment prevented
the weight loss (data not shown). In a parallel experiment,
we monitored the survival rate of BALB/c infected mice
with each of the phenolic compounds in a dose of 6mg/kg
body weight (data not shown). However, both phenolics didJournal of Parasitology Research 7
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Figure 6: Parasitemia of Plasmodium berghei-infected ANKA
strain-infected BALB/c mice after treatment with 50µLo ft h e
aqueousBalaniteextract(1,25g/100mL)incomparisontothePBS-
buﬀer-treated control. Administration was performed intraperi-
toneally on days 3, 2, and 1 before infection, at the day of infection
and on days 1, 2, 3, 4, 5, 6, 7, and 8 after infection. Giemsa-stained
smears were performed on days 4, 6, 8, 10, 12, and 15.
not reduce parasitemia in comparison to the control and,
therefore, did not prolong the survival of P. berghei infected
mice.
4. Discussion
B. aegyptiaca (Balanitaceae) is a widely distributed plant
in Africa and has been reported to show a lot of diﬀerent
biological activities, which were attributed to its saponin
constituents [16] mainly deriving from diosgenin as the
sole aglycone. Recent investigations proved a medicinal
evaluation for the ﬁxed oil of B. aegyptiaca fruits in vitro
[10]. In the past, moderate in vitro antiplasmodial activity
has been determined in an extract from B. aegyptiaca stem
bark with an IC50 value of 55µg/mL [17]. No antiplasmodial
activity was found in the mesocarp of the fruits from this
species. Since it was reported that a biosynthetic pathway to
diosgenin exists in germinating seeds of the plant [18], these
results challenged us to investigate an extract from Balanite
seeds obtained by Soxhlet extraction.
An aqueous dilution from the original extract in which
the ratio of seeds was equivalent to a ratio of 1:2000
seeds was tested for in vitro inhibition of the chloroquine-
susceptible P. falciparum strain NF54, resulting in an IC50
value of 68.26µg/µL±3,5. Although no saponin glycosides
deriving from the aglycone diosgenin were identiﬁed by
GC/MS (Kaiser unpublished), the crude, undiluted extract
seems to contain constituents which lyse RBCs.
In vitro activity is associated (Figure 4 blue curve) with
theoccurrenceoftheoximeof6-phenyl-2(H)-1,2,4-triazine-
5-one, since the absence of the compound in the Balanite
extract leads to a 50% lower inhibition of recombinant
plasmodial M18 Aspartyl Aminopeptidase (PfM18AAP)
(Figure 4, pink curve) compared to the crude extract where
theoximeof6-phenyl-2(H)-1,2,4-triazine-5-onewaspresent
(Figure 4 blue curve). However, the concentration of the
compound in the extract was too low for a successful
isolation and a proof of principle assay inhibiting growth of
Plasmodiuminvitro.T oourknowledge,therearenoprevious
studies with the compound in the literature so far.
Taken together, these data are supported by the deter-
mined Ki of 2.35µg/µL of the crude Balanite extract and
the extract which was depleted of the 6-phenyl-2(H)-1,2,4-
triazine-5-one oxime with a determined Ki of 4.8µg/µL.
Aminopeptidases are metalloproteases which cleave
aminoterminal amino acids during protein biosynthesis.
The Aspartyl Aminopeptidase exhibits exopeptidase activ-
ity exclusively against the N-terminal acidic amino acids
glutamate and aspartate from the host hemoglobin-derived
peptides. The enzyme is mainly located in the cytosol
but can also be traﬃcked to the parasitophorous vacuole.
Antisense-mediated knockdown of PfM18AAP results in a
lethal phenotype since the P. falciparum protein is expressed
in all erythrocytic stages [15].
The two phenolic compounds 2,4-di-tert-butyl-phenol
and 2,6-di-tert-butyl-phenol were identiﬁed by GC/MS
analysis (Figures 2-3) and contribute modestly to the
in vitro biological activity (Figure 5). The determined
IC50 values were 50.29µM±3 for 2,6-di-tert-butyl-phenol
and 47,82µM±2,5 for 2,4-di-tert-butyl-phenol, respectively
(Figures 5(b) and 5(d)). However, the determined IC50
valueof42.5µM±3,whenbothcompoundswerecombined,
appears to have a small additive eﬀect but did not lead to the
eradication of P. falciparum in vitro.
These compounds have been recently associated with the
antioxidant eﬀect of a methanolic extract from the centipede
Scolopendra subspinipes mutilans (Scolopendridae)w h i c hi s
used in traditional Chinese and Korean medicine for the
treatment of diseases such as spasm, childhood convulsions,
diphtheria and tetanus [19]. Moreover, 2,4-di-tert-butyl-
phenol exhibited antioxidant activity against LDL-oxidation
in a biological in vitro activity assay [19]. Consistent with
theobservationthat2,4-di-tert-butyl-phenolshowedantiox-
idant activity, the drug exhibited also radical scavenging
activity. Recently, the antioxidant capacity was also proven
for the oil present in Balanites aegyptiaca fruits in vitro [10].
The two phenolic compounds 2,4-di-tert-butyl-phenol
and 2,6-di-tert-butyl-phenol have been detected in a variety
of plant extracts. They occur as aromatic constituents in
volatile oil fractions of ﬁve diﬀerent species of Chinese
eaglewood [20]s u c ha sAquilaria sinensis (Thymelaeaceae),
in ﬂowers of Gynura cusimbua (Asteraceae)[ 21], in ﬂowers
of Clusia species (Guttiferae)[ 22] ,a n di nl e a v e so fPereskia
bleo (Cactaceae)[ 23]. Hitherto, the biogenesis of both
phenolic compounds in the plant has not been elucidated. A
possibleprecursormoleculewhichisastructuralanalogueof
these tertiary phenolics might be a butylated hydroxyanisole
deriving from the mevalonate pathway.
Secondly, in case of the extract obtained from Pereskia
bleo, Ali et al. [24] discussed the occurrence of both8 Journal of Parasitology Research
constituents as an uptake of the compounds from plastic
waste being in the soil. We have no data which support the
recent ﬁndings that the constituents are either of plant origin
or due to uptake of both constituents. The content of total
phenols in the methanol extract is 3.5% which is comparable
to that of Pereskia bleo [23] and might protect the fatty oil in
the seeds from oxidation.
Although the ﬁxed oil in B. aegyptiaca fruits exhibited
anticanceractivityinlung,liver,andbrainhumancarcinoma
cell lines, no cytotoxicity could be detected for the seed
extract (data not shown).
Hitherto, only two in vivo experiments in mice have been
performed with either the pure constituents of the plant or
the crude Balanite extract [6, 24]. The steroidal saponins
balanitin-6 and balanitin-7 increased the survival rate of
mice bearing murine L1210 leukemia grafts to the same
extent reported for vincristine [6].
As e c o n din vivo experiment was performed with a crude
Balanite extract to demonstrate moderate antihepatotoxic
activity in comparison with the standard hepatoprotective
silymarin [24]. The lyophilized extract of Balanites aegypti-
aca was administered orally for 5 consecutive days in a dose
of 1g/kg. On the last day of treatment, a hepatotoxic oral
dose of paracetamol (0.6g/kg) was given and the activity
of diagnostic liver enzymes were determined. B. aegyptiaca
had only a relatively modest hepatoprotective activity [24].
To analyze parasitemia, BALB/c infected mice were treated
with a crude, aqueous Balanite extract (50mL of 1,25g dry
extract/100mL solvent) injected intraperitoneally on a daily
basis, beginning on day 3,2,1 prior to infection, at the
day of infection, and continuing until 8daysp.i. Although
a decrease in parasitemia could be observed on day 12
(Figure 6),treatmentdidnotcleartheparasitesoverthistime
and therefore; did not prolong survival. The plasmodial M18
Aspartyl Aminopeptidase inhibitor is present in the extract,
however, its concentration might be too low to eradicate the
parasite. Toxicity issues prevented the performance of dose
escalationstudies.Theherbicidemetamitronisa4-amino-3-
methyl-6-phenyl-1,2,4,triazin-5-one and, therefore, closely
related from its structure to the 6-phenyl-2(H)-1,2,4-triazin-
5-one oxime. The LD50 for metamitron for a female rat is
approximately 1.4, and for a male rat it is 2.9mg/kg body
weight. It is a neurotoxic compound. Given that 6-phenyl-
2(H)-1,2,4-triazin-5-one oxime has the same eﬀect, it would
have enhanced the neurological symptoms in the infected
BALB/c mice independently from the parasitic infection.
Since there is a lack of knowledge with respect to the
half-life, absorption, distribution, and elimination of the
three identiﬁed compounds in a mammalian organism, we,
therefore, conclude that the crude plant extract in its current
form and concentration does not reduce parasitemia in vivo.
References
[1] E. Fletcher, “Traditional remedies—searching their natural
sources for the next malaria drug,” TDR News, vol. 79, pp. 8–
13, 2007.
[ 2 ]M .N d o y e ,I .Y .D i a l l o ,a n dK .G a s s a m a - D i a ,“ R e p r o d u c t i v e
biology in Balanites aegyptiaca (L.) Del., a semi-arid forest
tree,” African Journal of Biotechnology, vol. 3, no. 1, pp. 40–46,
2004.
[3] A. M. Mohamed, W. Wolf, and W. E. L. Spiess, “Physical,
morphological and chemical characteristics, oil recovery and
fatty acid composition of Balanites aegyptiaca Del. kernels,”
Plant Foods for Human Nutrition, vol. 57, no. 2, pp. 179–189,
2002.
[4] H. D. Neuwinger, “Plants used for poison ﬁshing in tropical
Africa,” Toxicon, vol. 44, no. 4, pp. 417–430, 2004.
[5] S. M. Maregesi, L. Pieters, O. D. Ngassapa et al., “Screening
of some Tanzanian medicinal plants from Bunda district for
antibacterial, antifungal and antiviral activities,” Journal of
Ethnopharmacology, vol. 119, no. 1, pp. 58–66, 2008.
[6] C. Gnoula, V. M´ egalizzi, N. De N` eve et al., “Balanitin-6 and -
7: diosgenyl saponins isolated from Balanites aegyptiaca Del.
display signiﬁcant anti-tumor activity in vitro and in vivo,”
InternationalJournalofOncology,vol.32,no.1,pp.5–15,2008.
[7] S. L. Kela, R. A. Ogunsusi, V. C. Ogbogu, and N. Nwude,
“Screening of some Nigerian plants for molluscicidal activity,”
Revue d’´ E l e v a g ee td eM ´ edecine V´ et´ erinaire des Pays Tropicaux,
vol. 42, no. 2, pp. 195–202, 1989.
[8] W. S. Koko, H. S. Abdalla, M. Galal, and H. S. Khalid, “Eval-
uation of oral therapy on Mansonial Schistosomiasis using
single dose of Balanites aegyptiaca fruits and praziquantel,”
Fitoterapia, vol. 76, no. 1, pp. 30–34, 2005.
[9] B. P. Chapagain, V. Saharan, and Z. Wiesman, “Larvicidal
activity of saponins from Balanites aegyptiaca callus against
Aedes aegypti mosquito,” Bioresource Technology, vol. 99, no.
5, pp. 1165–1168, 2008.
[ 1 0 ] H .A .A lA s h a a l ,A .A .F a r g h a l y ,M .M .A b dE lA z i z ,a n dM .A .
Ali, “Phytochemical investigation and medicinal evaluation of
ﬁxed oil of Balanites aegyptiaca fruits (Balantiaceae),” Journal
of Ethnopharmacology, vol. 127, no. 2, pp. 495–501, 2010.
[11] M.B.Moloney,A.R.Pawluk,andN.R.Ackland,“Plasmodium
falciparum growth in deep culture,” Transactions of the Royal
Society of Tropical Medicine and Hygiene,v o l .8 4 ,n o .4 ,p p .
516–518, 1990.
[12] W. Trager and J. Williams, “Extracellular (axenic) devel-
opment in vitro of the erythrocytic cycle of Plasmodium
falciparum,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 89, no. 12, pp. 5351–5355,
1992.
[13] A. Kaiser, A. Gottwald, W. Maier, and H. M. Seitz, “Targeting
enzymes involved in spermidine metabolism of parasitic
protozoa—a possible new strategy for anti-parasitic treat-
ment,” Parasitology Research, vol. 91, no. 6, pp. 508–516, 2003.
[14] S. Singh, S. K. Puri, S. K. Singh, R. Srivastava, R. C.
Gupta, and V. C. Pandey, “Characterization of simian malarial
parasite (Plasmodium knowlesi)-induced putrescine transport
in rhesus monkey erythrocytes,” The Journal of Biological
Chemistry, vol. 272, no. 21, pp. 13506–13511, 1997.
[15] F. Teuscher, J. Lowther, T. S. Skinner-Adams et al., “The
M18 aspartyl aminopeptidase of the human malaria parasite
Plasmodium falciparum,” The Journal of Biological Chemistry,
vol. 282, no. 42, pp. 30817–30826, 2007.
[16] Eskander M., Pharmacological and toxicological eﬀects of
Balanitesaegyptiacaonlaboratoryanimals,M.S.thesis,Faculty
of Veterinary Medicine, University of Khartoum, Khartoum,
Sudan, 1982.
[17] A. El-Tahir, G. M. H. Satti, and S. A. Khalid, “Antiplasmodial
activity of selected Sudanese medicinal plants with emphasis
on Acacia nilotica,” Phytotherapy Research, vol. 13, no. 6, pp.
474–478, 1999.Journal of Parasitology Research 9
[18] R.Hardman and E.A.Sofowora, “Biosynthesis of diosgenin in
germinating seeds of Balanites aegyptiaca,” Planta Medica, vol.
20, no. 3, pp. 193–198, 1971.
[19] M. A. Yoon, T. S. Jeong, D. S. Park et al., “Antioxidant eﬀects
of quinoline alkaloids and 2,4-di-tert-butylphenol isolated
from Scolopendra subspinipes,” Biological and Pharmaceutical
Bulletin, vol. 29, no. 4, pp. 735–739, 2006.
[20] W. L. Mei, Y. B. Zeng, J. Liu, and H. F. Dai, “GC-MS analysis
of volatile constituents from ﬁve diﬀerent kinds of Chinese
eaglewood,” Zhong Yao Cai, vol. 30, no. 5, pp. 551–555, 2007.
[21] V. S. Rana and M. A. Blazquez, “Constituents of the essential
oil of Meriandra bengalensis benth. Leaves from India,”
Essential Oil Research, vol. 19, pp. 21–22, 2007.
[22] P. C. De, V. Bittrich, G. J. Shepherd, A. V. Lopes, and A.
J. Marsaioli, “The ecological and taxonomic importance of
ﬂower volatiles of Clusia species (Guttiferae),” Phytochemistry,
vol. 56, no. 5, pp. 443–452, 2001.
[23] S. N. A.Malek, S. K.Shin, N. A.Wahab, and H. Yaacob, “Cyto-
toxic components of Pereskia bleo (Kunth) DC. (Cactaceae)
leaves,” Molecules, vol. 14, no. 5, pp. 1713–1724, 2009.
[24] B. H. Ali, A. K. Bashir, and R. A. Rasheed, “Eﬀect of the
traditional medicinal plants Rhazya stricta, Balanitis aegypti-
aca and Haplophylum tuberculatum on paracetamol-induced
hepatotoxicity in mice,” Phytotherapy Research, vol. 15, no. 7,
pp. 598–603, 2001.